Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis

Zhang, Guoqiao; Zeng, Rong; Wang, Kai; Yinzhuoyang, A; Li, Linhai; Gong, Ke

doi:10.3892/ol.2019.9894

Cited by 3 publications

(2 citation statements)

References 32 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other nonrandomized Six studies [70][71][72][73][74][75] 51 studies [76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99] 18 studies [127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][142][143][144] Three studies [145][146][147] Abbreviation: RCTs, randomized controlled trials.…”

Section: Summary Of Key Trials Published Prior To 2008mentioning

confidence: 99%

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Vogelbaum

Brown

Messersmith

et al. 2022

JCO

348

222

View full text Add to dashboard Cite

PURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines .

show abstract

Section: Summary Of Key Trials Published Prior To 2008mentioning

confidence: 99%

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Vogelbaum

Brown

Messersmith

et al. 2022

JCO

348

222

View full text Add to dashboard Cite

show abstract

“…LUAD can be detected by radiography, ne needle aspiration biopsy and pathological analysis, while the expression variations of signaling molecules in LUAD also provide new candidates for diagnosis [1,2]. Recently, treatment methods for LUAD, including surgery, chemotherapy or molecular-targeted therapy, and even immunotherapy, have been employed [3][4][5][6][7]. Interestingly, traditional Chinese medicine (TCM) treatment can alleviate the symptoms caused by LUAD and ease multidrug resistance, has a synergistic and detoxifying effect on radiotherapy and chemotherapy, and has become an important component of comprehensive treatment [8,9].…”

Section: Introductionmentioning

confidence: 99%

Potential Therapeutic Value of Mangiferin for Lung Adenocarcinoma (Luad): A Comprehensive Study Based on in Vitro Experiments and Bioinformatics

Liu

Chi

Meng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD), which is the most common lung cancer type in never-smokers and primarily occurs in women, requires effective treatment methods. Mangiferin is a polyphenol widely found in mango trees and has been reported to have chemotherapeutic and preventive potential against various types of cancer. Thus, we investigated the potential therapeutic value of mangiferin for LUAD.Methods: Cell lines A549, H2030 and H1299 were processed with mangiferin to detect and screen for differentially expressed lncRNAs and mRNAs. Close associations between extracted common lncRNAs and mRNAs were identified for lncRNA-mRNA network construction. Based on the network and an online database, target lncRNAs, target genes and meaningful lncRNA-mRNA pairs were identified, and signaling pathway analysis was performed.Results: The top 200 lncRNA-mRNA pairs were used to construct the network. We identified 12 target lncRNAs and 18 target genes. Gene nodes in the network were mostly visualized on the PI3K-Akt signaling pathway (P < 0.01). Furthermore, lncRNA-mRNA pairs that contained the genes ARHGAP29, BRIX1, CD109, CDK1, CTNNAL1, DAB2IP, DDIT4L, GPR162, ICAM5, KCNAB3 and MMP7 were considered to be meaningful lncRNA-mRNA pairs affected by mangiferin in LUAD.Conclusions: Our study provided a comprehensive understanding of the potential therapeutic value of mangiferin for LUAD.

show abstract

miR-17-5p/HOXA7 Is a Potential Driver for Brain Metastasis of Lung Adenocarcinoma Related to Ferroptosis Revealed by Bioinformatic Analysis

et al. 2022

View full text Add to dashboard Cite

ObjectivesPresent study aims to identify the essential mRNAs responsible for the development of brain neurovascular-related metastases (BNM) among lung adenocarcinoma (LUAD) patients. Further, we attempted to predict brain metastases more accurately and prevent their development in LUAD patients.MethodsTranscriptome data analysis was used to identify differentially expressed mRNAs (DEMs) associated with brain metastasis, and thereby the ferroptosis index (FPI) is calculated using a computational model. Meanwhile, the DEmRNAs linked with FPI, and brain metastasis were derived by the intersection of these two groups of DEMs. We also constructed a ceRNA network containing these DEmRNAs, identifying the HCP5 /hsa-miR-17-5p/HOXA7 axis for analysis. Further, a clinical cohort was employed to validate the regulatory roles of molecules involved in the ceRNA regulatory axis.ResultsHere we report the development of a ceRNA network based on BNM-associated DEMs and FPI-associated DEmRNAs which includes three core miRNAs (hsa-miR-338-3p, hsa-miR-429, and hsa-miR-17-5p), three mRNAs (HOXA7, TBX5, and TCF21), and five lncRNAs (HCP5, LINC00460, TP53TG1). Using gene set enrichment analysis (GSEA) and survival analysis, the potential axis of HCP5 /hsa-miR-17-5p/HOXA7 was further investigated. It is found that HOXA7 and ferroptosis index are positively correlated while inhibiting tumor brain metastasis. It may be that HCP5 binds competitively with miR-17-5p and upregulates HOXA7 to increase iron death limiting brain cancer metastasesConclusionsThe expression of both HOXA7 and HCP5 is positively correlated with FPI, indicating a possible link between ferroptosis and BNM. According to the results of our study, the ferroptosis-related ceRNA HCP5 /hsa-miR-17-5p/HOXA7 axis may contribute to the development of BNM in LUAD patients.

show abstract

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis

Cited by 3 publications

References 32 publications

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Potential Therapeutic Value of Mangiferin for Lung Adenocarcinoma (Luad): A Comprehensive Study Based on in Vitro Experiments and Bioinformatics

miR-17-5p/HOXA7 Is a Potential Driver for Brain Metastasis of Lung Adenocarcinoma Related to Ferroptosis Revealed by Bioinformatic Analysis

Contact Info

Product

Resources

About